StreetAlpha.app
Home › Stocks › DFTX

Definium Therapeutics, Inc. (DFTX)

Healthcare
Members
LATEST PRICE

Definium Therapeutics develops treatments based on psychedelic compounds for brain health disorders such as anxiety, depression and autism. DFTX reports earnings on Mon, Nov 9, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 10 firms (10 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 6 whale options trades in DFTX, 67% of them bullish and 33% bearish. In the past 30 days there were 4 dark pool prints.

Prices, price targets and earnings estimates for DFTX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is DFTX in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 9
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
Strong Buy
Based on 10 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
10firms
10 Buy0 Hold0 Sell
Each firm's latest rating on DFTX in the past 90 days
Average 12-month target
Price targets for DFTXThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
JP MorganInitiated
Oct 9Buy
Canaccord GenuityTarget raised
Sep 15Buy
BairdTarget raised
Sep 15Buy
NeedhamReiterated
Sep 14Buy
B of A SecuritiesInitiated
Aug 18Buy
DateFirmActionRatingPrice target
Oct 9JP MorganInitiatedBuy
Sep 15Canaccord GenuityTarget raisedBuy
Sep 15BairdTarget raisedBuy
Sep 14NeedhamReiteratedBuy
Aug 18B of A SecuritiesInitiatedBuy
Loading…

Whale Options Flow

90D
Total alerts
6
Bullish
4
67%
Bearish
2
33%
Date span
Aug 5 – Oct 1
Loading…

Dark Pool

30D
Prints
4
Notional
Members
Largest print
Members
Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DFTX is in one of them and how their past DFTX trades turned out.

See how it works→ View all auto pilots→
DFTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DFTX in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Definium Therapeutics

Definium Therapeutics is a drug developer based in New York that is working on treatments for brain health conditions. Its main product candidates are derived from psychedelic and empathogen compounds. The lead candidate, DT120, is being tested in adults with generalized anxiety disorder and major depressive disorder, and a second candidate, DT402, is being studied in adults with autism spectrum disorder. None of its products are approved for sale yet, and the company is aiming to offer them to patients under medical care.

Headquarters
New York, NY
Summary based on the company’s 2026 annual report (10-K) ↗